US Pharma MarketingFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’ is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
In the race to turn CAR-T cell therapies against autoimmune diseases, Cabaletta has always been blazing its own trail.
Source: FierceBiotech